Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

eg sa-nv - vindesine sulfate 5 mg - powder for solution for injection - 5 mg - vindesine sulfate 5 mg - vindesine

New Zealand - English - Medsafe (Medicines Safety Authority)

eli lilly and company (nz) limited - vindesine sulfate 5mg;   - powder for injection - 5 mg - active: vindesine sulfate 5mg  

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

genus pharmaceuticals ltd - vindesine sulfate - powder for solution for injection - 5mg

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - vindesine sulfate, quantity: 5 mg - injection, powder for - excipient ingredients: mannitol - this product accepted for registration/listing as 'currently supplied' at the time of commencement of the act. indications held in artg paper records. (old code) eldisine is indicated in the palliative treatment of the following: acute lymphocytic leukaemia of childhood resistant to other agents. blastic crises of chronic myeloid leukaemia in adults. non-small cell lung cancer. it should be noted that eldisine is usually given in combination with other oncolytic agents.

Canada - English - Health Canada

eli lilly canada inc - vindesine sulfate - powder for solution - 5mg - vindesine sulfate 5mg - antineoplastic agents

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - vincristine sulfate, quantity: 1 mg/ml - injection, solution - excipient ingredients: sulfuric acid; mannitol; water for injections; sodium hydroxide - vincristine sulfate is indicated in acute leukaemia - current practices of cancer chemotherapy involve the simultaneous use of several agents. for enhanced therapeutic effect without additive toxicity, agents with different dose-limiting clinical toxicities and different mechanisms of action are generally selected. it is rarely possible to achieve equally good results with single agent treatment. thus vincristine sulfate is often chosen as part of polychemotherapy because of its unique clinical toxicity (neuropathy). see dosage and administration for possible increased toxicity when used in combination therapy. it has been shown to be useful in combination with other oncolytic agents in hodgkin's disease, non-hodgkin's malignant lymphomas (lymphocytic, mixed-cell, histiocytic, undifferentiated, nodular and diffuse types), rhabdomyosarcoma, neuroblastoma, wilm's tumour, osteogenic sarcoma, mycosis fungoides, ewing's sarcoma, carcinoma of the uterine cervix, breast cancer, malignant melanoma, oat-cell carcinoma

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - vincristine sulfate, quantity: 1 mg/ml - injection, solution - excipient ingredients: water for injections; mannitol; sulfuric acid; sodium hydroxide - vincristine sulfate is indicated in acute leukaemia - current practices of cancer chemotherapy involve the simultaneous use of several agents. for enhanced therapeutic effect without additive toxicity, agents with different dose-limiting clinical toxicities and different mechanisms of action are generally selected. it is rarely possible to achieve equally good results with single agent treatment. thus vincristine sulfate is often chosen as part of polychemotherapy because of its unique clinical toxicity (neuropathy). see dosage and administration for possible increased toxicity when used in combination therapy. it has been shown to be useful in combination with other oncolytic agents in hodgkin's disease, non-hodgkin's malignant lymphomas (lymphocytic, mixed-cell, histiocytic, undifferentiated, nodular and diffuse types), rhabdomyosarcoma, neuroblastoma, wilm's tumour, osteogenic sarcoma, mycosis fungoides, ewing's sarcoma, carcinoma of the uterine cervix, breast cancer, malignant melanoma, oat-cell carcinoma

Australia - English - Department of Health (Therapeutic Goods Administration)

vincristine sulfate -

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - vincristine sulfate, quantity: 1 mg/ml - injection, solution - excipient ingredients: mannitol; water for injections; sodium hydroxide; sulfuric acid - vincristine is used primarily in the treatment of acute leukaemia, usually as a component of various chemotherapeutic regimens. it has also been used as part of combination therapy in the treatment of hodgkin's disease, non-hodgkin's malignant lymphomas, rhabdomyosarcoma, neuroblastoma, wilm's tumour, osteogenic sarcoma, mycosis fungoides, ewing's sarcoma, carcinoma of the uterine cervix, breast cancer, malignant melanoma, oat-cell carcinoma of the lung and gynaecological tumours of childhood. vincristine may be useful in patients with true idiopathic thrombocytopenic purpura resistant to the usual treatment, but not recommended as primary treatment for this disorder

Japan - English - すりの適正使用協議会 RAD-AR Council, Japan

nichi-iko pharmaceutical co.,ltd - vindesine sulfate - injection